Patents by Inventor Stuart Ince

Stuart Ince has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazopyridazines as Akt kinase inhibitors
    Patent number: 9604989
    Abstract: The present invention relates to a method for the treatment of a cancer that is sensitive to Pi3K/Akt pathway inhibition by administering a therapeutically effective amount of a compound of formula (I)
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: March 28, 2017
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Hans Briem, Ulf Bömer
  • Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
    Patent number: 9340528
    Abstract: The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R2, R3, R4, R6, R7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: May 17, 2016
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Benjamin Bader, Ulf Bömer, Stuart Ince, Marcus Koppitz, Philip Lienau, Tobias Marquardt, Duy Nguyen, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
  • Substituted imidazopyrazines as Akt kinase inhibitors
    Patent number: 9260435
    Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: February 16, 2016
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Ulf Bömer
  • IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS
    Publication number: 20150368250
    Abstract: Imidazopyridazines of formula (I) a process for their production and the use thereof.
    Type: Application
    Filed: July 6, 2015
    Publication date: December 24, 2015
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Lars BÄRFACKER, William SCOTT, Andrea HÄGEBARTH, Stuart INCE, Hartmut REHWINKEL, Oliver POLITZ, Roland NEUHAUS, Hans BRIEM, Ulf BÖMER
  • Imidazopyridazines as Akt kinase inhibitors
    Patent number: 9206185
    Abstract: The application relates to imidazopyridazines of formula (I) which are useful as Akt inhibitors suitable for the treatment of cancer, and processes for their production and the use thereof.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: December 8, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Hans Briem, Ulf Bömer
  • Substituted imidazo[1,2-a]pyrimidines and —pyridines
    Patent number: 8975265
    Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: March 10, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stuart Ince, Andrea Hägebarth, Oliver Politz, Roland Neuhaus, Ulf Bömer, William Scott
  • Fused pyrimidines
    Patent number: 8957064
    Abstract: Compounds of formula (I) or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer, wherein ring B and the pyrimidine to which it is fused, R4, R5, R6, R7, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: February 17, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Matthias Vennemann, Thomas Bär, Thomas Maier, Swen Hölder, Gerrit Beneke, Florian Dehmel, Armin Zülch, Andreas Strub, Stuart Ince, Hartmut Rehwinkel, Ningshu Liu, Ulf Bömer, Barbara Beckers
  • SUBSTITUTED IMIDAZOPYRAZINES AS AKT KINASE INHIBITORS
    Publication number: 20150005309
    Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: January 8, 2013
    Publication date: January 1, 2015
    Inventors: Lars Bärfacker, William Scott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Ulf Bömer
  • IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS
    Publication number: 20140113901
    Abstract: Imidazopyridazines of formula (I) a process for their production and the use thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: April 24, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Lars Bärfacker, William Sott, Andrea Hägebarth, Stuart Ince, Hartmut Rehwinkel, Oliver Politz, Roland Neuhaus, Hans Briem, Ulf Bömer
  • Substituted Imidazo[1,2-a]pyrimidines and -pyridines
    Publication number: 20130190332
    Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: July 7, 2011
    Publication date: July 25, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stuart Ince, Andrea Hägebarth, Oliver Politz, Roland Neuhaus, Ulf Bömer, William Scott
  • BICYCLIC PYRIMIDINES
    Publication number: 20130184273
    Abstract: Compounds of formula (I), which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: July 11, 2011
    Publication date: July 18, 2013
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Stuart Ince, Hartmut Rehwinkel, Andrea Hägebarth, Oliver Politz, Roland Neuhaus, Ulf Bömer
  • SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS
    Publication number: 20120263708
    Abstract: The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R2, R3, R4, R6, R7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: August 24, 2010
    Publication date: October 18, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Benjamin Bader, Ulf Bömer, Stuart Ince, Marcus Koppitz, Philip Lienau, Tobias Marquardt, Duy Nguyen, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
  • Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Patent number: 7906533
    Abstract: The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: March 15, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp
  • Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
    Patent number: 7902229
    Abstract: The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Bayer Schering Pharma AG
    Inventors: Rolf Bohlmann, Martin Haberey, Andreas Huth, Stuart Ince, Martin Krueger, Karl-Heinz Thierauch, Holger Hess-Stumpp, Andreas Reichel
  • Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    Patent number: 7846928
    Abstract: The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: December 7, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Ulf Boemer
  • Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
    Patent number: 7825114
    Abstract: The invention relates to substituted aminopyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted aminopyrazolopyridines, to methods of preparing said substituted aminopyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: November 2, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Wolfgang Schwede, Antonius M. Laak Ter
  • VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
    Patent number: 7517894
    Abstract: VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: April 14, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Andreas Huth, Ludwig Zorn, Martin Krueger, Stuart Ince, Karl Heinz Thierauch, Andreas Menrad, Martin Haberey, Holger Hess-Stumpp
  • SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
    Publication number: 20090018129
    Abstract: The invention relates to substituted aminopyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted aminopyrazolopyridines, to methods of preparing said substituted aminopyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
    Type: Application
    Filed: June 12, 2007
    Publication date: January 15, 2009
    Inventors: Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Wolfgang Schwede, Antonius M. Laak Ter
  • SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
    Publication number: 20090005373
    Abstract: The invention relates to substituted sulfonamido-macrocycles according to the general formula (I): in which R1, R2, R4, R5, A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said substituted sulfonamido-macrocycles, to methods of preparing said substituted sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
    Type: Application
    Filed: June 20, 2007
    Publication date: January 1, 2009
    Inventors: Ingo Hartung, Hans Briem, Georg Kettschau, Karl-Heinz Thierauch, Ulrich Lucking, Ulf Bomer, Martina Schafer, Stuart Ince
  • SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
    Publication number: 20080058326
    Abstract: The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.
    Type: Application
    Filed: June 12, 2007
    Publication date: March 6, 2008
    Inventors: Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Ulf Boemer